Cadrenal Therapeutics, Inc.

Executive Summary

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a clinical-stage biopharmaceutical company focused on the development of tecarfarin, a novel, once-daily oral vitamin K antagonist (VKA) designed to provide safer, more predictable anticoagulation for patients with high unmet need—specifically those with end-stage renal disease (ESRD) and atrial fibrillation (AF), and patients with left ventricular assist devices (LVADs). The company’s lead candidate leverages a unique metabolic pathway that bypasses the CYP450 enzyme system, potentially reducing the drug-drug interactions and dietary variability that limit current VKAs like warfarin.

Government Reliance & Contracts

Cadrenal does not currently derive direct revenue from federal contracts, but it maintains a strategic, non-dilutive collaboration with the U.S. Department of Defense. In August 2023, the company entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate tecarfarin for the prevention of venous thromboembolism in trauma patients. This partnership provides access to military clinical infrastructure, trauma expertise, and potential future procurement pathways if the drug is approved for use in combat casualty care. While no federal dollars flow to Cadrenal under the CRADA, the relationship significantly de-risks the trauma indication and opens a door to a government end-market.

Moats & Key Technology

• Orphan Drug Exclusivity: Tecarfarin has received Orphan Drug Designation from the FDA for two indications—prevention of thromboembolism in patients with ESRD and AF, and for patients with LVADs. If approved, these designations confer 7 years of market exclusivity in the U.S., creating a formidable regulatory moat.
• Differentiated Pharmacology: Unlike warfarin, tecarfarin is metabolized primarily by carboxylesterase enzymes, not the CYP450 system. This avoids the common drug-drug interactions and genetic polymorphisms that complicate warfarin dosing, particularly in the polypharmacy-heavy ESRD and LVAD populations.
• Intellectual Property: The company holds a portfolio of issued U.S. and international patents covering composition of matter, methods of use, and formulations of tecarfarin, with protection extending into the late 2030s. This patent estate blocks generic competition and secures the commercial runway.
• Regulatory Pathway: Cadrenal has aligned with the FDA on a single pivotal Phase 3 trial for the ESRD/AF indication, reducing clinical risk and time to market compared to programs requiring multiple studies.

Capital & Shadow Backers

Cadrenal went public via an initial public offering in January 2023, raising approximately $7.5 million at $5.00 per share. Since then, the company has relied on a tight network of insider and affiliated investors. A Form D filing dated July 16, 2026, reveals a $8,843,849 private placement—structured as a PIPE—from a group of existing stakeholders and board members:

• Quang X. Pham (Founder, Chairman & CEO)
• John P. Sharp (Director)
• James J. Ferguson (Director)
• Jeffrey S. Cole (CFO)
• Lee Golden (Director)
• John R. Murphy (Director)
• Glynn Wilson (Director)

This insider-led financing underscores deep commitment from leadership but also highlights the company’s reliance on a concentrated, relationship-based funding base rather than broad institutional support. The capital extends the cash runway through key clinical milestones.

Recent Catalysts

• CRADA with U.S. Army (August 2023): Initiated a trauma-focused development track, expanding tecarfarin’s addressable market and providing a non-dilutive validation channel.
• Orphan Drug Designations: Secured for both ESRD/AF and LVAD indications, locking in market exclusivity and eligibility for FDA fee waivers and tax credits.
• Phase 3 Preparations: The company has finalized the pivotal trial design for tecarfarin in ESRD patients with AF and is actively preparing for trial initiation, with topline data expected to serve as the primary value inflection point.
• Insider PIPE (July 2026): The $8.8 million raise from directors and executives signals confidence in the upcoming clinical program and provides near-term funding to reach the next data readout.
• Regulatory Clarity: Ongoing FDA interactions have confirmed a single Phase 3 trial requirement, streamlining the path to a New Drug Application (NDA) submission.